Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Uscom Limited ( (AU:UCM) ) has issued an update.
Uscom Limited reported a sharp contraction in revenue and other income for the half year to 31 December 2025 after selling all of its international subsidiaries and ceasing overseas operations. The company’s net tangible asset backing fell to 0.1 cents per share and no dividend was declared, underscoring the impact of this strategic withdrawal on its balance sheet and investor returns.
Despite reduced trading activity and an underlying operating loss, Uscom posted a net profit of $821,243 for the period, driven by a $2.35 million pre-tax gain on the sale of its subsidiaries for $2.59 million. With trading activities halted and the accounts now prepared on a basis other than going concern, the group has effectively transitioned out of its previous operating model, raising questions over its future direction and value for remaining shareholders.
The most recent analyst rating on (AU:UCM) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Uscom Limited stock, see the AU:UCM Stock Forecast page.
More about Uscom Limited
Uscom Limited is an Australian-listed medical technology company that has historically operated through international subsidiaries. The group has focused on commercialising and distributing its clinical devices and related solutions across multiple overseas markets, though these operations have now been discontinued following the recent disposals.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$3.12M
See more data about UCM stock on TipRanks’ Stock Analysis page.